Cutaneous reactions with tenofovir disoproxil fumarate: A report of nine cases

AIDS

Volumn 21, Issue 10, 2007, Pages 1370-1373

  Lockhart, Staci M ^a   Rathbun, R Chris ^a   Stephens, Johnny R ^b   Baker, Damon L ^b   Drevets, Douglas A ^a   Greenfield, Ronald A ^a   Salvaggio, Michelle R ^a   Vincent, Simi ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS EMTRICITABINE PLUS FOSAMPRENAVIR PLUS RITONAVIR PLUS TENOFOVIR DISOPROXIL; AMPRENAVIR PHOSPHATE; ANTIHISTAMINIC AGENT; ATAZANAVIR; ATAZANAVIR PLUS DIDANOSINE PLUS EFAVIRENZ PLUS RITONAVIR; ATAZANAVIR PLUS EMTRICITABINE PLUS RITONAVIR PLUS TENOFOVIR DISOPROXIL; ATAZANAVIR PLUS LAMIVUDINE PLUS RITONAVIR PLUS TENOFOVIR DISOPROXIL PLUS ZIDOVUDINE; DIDANOSINE; DIDANOSINE PLUS EFAVIRENZ PLUS TENOFOVIR DISOPROXIL; DIDANOSINE PLUS LOPINAVIR PLUS RITONAVIR PLUS TENOFOVIR DISOPROXIL; DIDANOSINE PLUS LOPINAVIR PLUS RITONAVIR PLUS ZIDOVUDINE; DIDANOSINE PLUS NELFINAVIR PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LAMIVUDINE PLUS NELFINAVIR PLUS ZIDOVUDINE; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR; NELFINAVIR; RITONAVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL ARTICLE; DELAYED HYPERSENSITIVITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FIXED DRUG ERUPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMEDIATE TYPE HYPERSENSITIVITY; MACULOPAPULAR RASH; MALE; PAPULOVESICULAR RASH; PRIORITY JOURNAL; PRURITUS; SKIN MANIFESTATION; TONGUE EDEMA; TREATMENT OUTCOME; URTICARIA; VESICULAR RASH;

ADENINE; ADULT; DRUG ERUPTIONS; DRUG THERAPY, COMBINATION; EXANTHEMA; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; SKIN;

EID: 34249982555     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32811ebf9e     Document Type: Article

References (10)

1. O'Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003; 34:407-414.
2. Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993; 328:1670-1674.
3. Staszewiski S, Gallant J, Pozniak AL, Sulieman JMAH, De Jesus E, Koenig E, et al. Efficacy and safety of tenofovir disoproxil fumarate (TDF) versus stavudine (d4T) when used in combination with lamivudine (3TC) and efavirenz (EFV) in HIV-1 infected patients naive to antiretroviral therapy (ART): 48-week interim results. In: Program and abstracts of the XIVth International AIDS Conference. Barcelona, Spain, 7-12 July 2002.[Abstract LbOr17].
4. Pozniak A, Gallant JE, De Jesus E, Campo R, Arribus JR, Gazzard B, et al. Superior outcome for tenofovir DF (TDF), emtricitabine (FTC) and efavirenz (EFV) compared to fixed dose zidovudine/lamivudine (CBV) and EFV in antiretroviral naive patients. In: 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil, 24-27 July 2005 [Abstract WeOa0202].
5. Viread package insert. Gilead Sciences. Foster City, CA; May 2005. in press.
6. Panel on Clinical Practices for the Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at: http://aidsinfo.nih.gov. Accessed: 14 July 2006.
7. Bersoff-Matcha SJ, Miller WC, Aberg JA, van der Horst C, Hamrick HJ Jr, Powderly WG, Mundy LM. Sex differences in nevirapine rash. Clin Infect Dis 2001; 32:124-129.
8. Stern JO, Robinson PA, Love J, Lanes S, Imperial MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003; 34 (Suppl. 1):S21-S33.
9. Den Brinker M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van Leeuwen R, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14:2895-2902.
10. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.